K
Kathelijne Peerlinck
Researcher at Katholieke Universiteit Leuven
Publications - 153
Citations - 5856
Kathelijne Peerlinck is an academic researcher from Katholieke Universiteit Leuven. The author has contributed to research in topics: Haemophilia & Haemophilia A. The author has an hindex of 39, co-authored 145 publications receiving 5221 citations. Previous affiliations of Kathelijne Peerlinck include Ludwig Institute for Cancer Research & University of Mainz.
Papers
More filters
Journal ArticleDOI
Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders.
Flora Peyvandi,Roberta Palla,Marzia Menegatti,Simona Maria Siboni,Susan Halimeh,B. Faeser,Helen Pergantou,H. Platokouki,Paul Giangrande,Kathelijne Peerlinck,Tiraje Celkan,Nihal Özdemir,Christoph Bidlingmaier,J. Ingerslev,Muriel Giansily-Blaizot,J.-F. Schved,R. Gilmore,Alain Gadisseur,Majda Benedik-Dolničar,Lidija Kitanovski,Danijela Mikovic,Khaled M. Musallam,F. R. Rosendaal +22 more
TL;DR: The aim of the EN‐RBD is to bridge the gap between knowledge and practise in the care of patients with RBDs and to provide real-time information about bleeding disorders to improve the quality of life for patients.
Journal ArticleDOI
Factor VIII gene inversions in severe hemophilia A: results of an international consortium study
Stylianos E. Antonarakis,J. P. Rossiter,M. Young,J. Horst,P. De Moerloose,S. S. Sommer,Rhett P. Ketterling,H. H. Kazazian,Claude Negrier,Christine Vinciguerra,Jane Gitschier,Michel Goossens,E. Girodon,N. Ghanem,F. Plassa,Jean-Maurice Lavergne,M. Vidaud,J. M. Costa,Y. Laurian,S. W. Lin,S. R. Lin,M. C. Shen,David Lillicrap,Sherryl A. M. Taylor,S. Windsor,Sophie Valleix,K. Nafa,Y. Sultan,Marc Delpech,Cindy L. Vnencak-Jones,John A. Phillips,Rolf Ljung,E. Koumbarelis,A. Gialeraki,T. Mandalaki,P. V. Jenkins,Peter William Collins,K. J. Pasi,Anne Goodeve,Ian R. Peake,F. E. Preston,Marianne Schwartz,Elma Scheibel,Jørgen Ingerslev,David Neil Cooper,David Stuart Millar,V. V. Kakkar,F. Giannelli,J.A. Naylor,E. F. Tizzano,M. Baiget,M. Domenech,Carmen Altisent,J. Tusell,M. Beneyto,J. I. Lorenzo,Christine Gaucher,Claudine Mazurier,Kathelijne Peerlinck,Gert Matthijs,Jj. Cassiman,Jozef Vermylen,P. G. Mori,M. Acquila,D. Caprino,Hiroshi Inaba +65 more
TL;DR: The presence of factor VII inversions is not a major predisposing factor for the development of factor VIII inhibitors; however, slightly more patients with severe hemophilia A and factor VIII inversions develop inhibitors than patients without inversions.
Journal ArticleDOI
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study
Steven W. Pipe,Midori Shima,Michaela Lehle,Amy D. Shapiro,Sammy Chebon,Katsuyuki Fukutake,Nigel S. Key,Agnès Portron,Christophe Schmitt,Maria Podolak-Dawidziak,Nives Selak Bienz,Cédric Hermans,Avrita Campinha-Bacote,Anna Kiialainen,Kathelijne Peerlinck,Gallia G. Levy,Víctor Jiménez-Yuste +16 more
TL;DR: Emicizumab given once every 4 weeks showed clinically meaningful bleed control while being well tolerated, and could improve patient care by decreasing treatment burden and increasing adherence to effective prophylaxis, potentially decreasing the development of secondary complications for people with haemophilia A.
Journal ArticleDOI
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A
Corien L. Eckhardt,Alice S. van Velzen,Marjolein Peters,Jan Astermark,Paul P. T. Brons,Giancarlo Castaman,Marjon H. Cnossen,Natasja Dors,Carmen Escuriola-Ettingshausen,Karly Hamulyák,Daniel P. Hart,Charles R. M. Hay,Saturnino Haya,Waander L. van Heerde,Cedric Hermans,Margareta Holmström,Víctor Jiménez-Yuste,Russell Keenan,Robert Klamroth,Britta A P Laros-van Gorkom,Frank W.G. Leebeek,Ri Liesner,Anne Mäkipernaa,Christoph Male,Evelien P. Mauser-Bunschoten,Maria Gabriella Mazzucconi,Simon McRae,Karina Meijer,Michael J. Mitchell,Massimo Morfini,M.R. Nijziel,Johannes Oldenburg,Kathelijne Peerlinck,Pia Petrini,H Platokouki,Sylvia Reitter-Pfoertner,Elena Santagostino,Piercarla Schinco,Frans J. Smiers,B. Siegmund,Annarita Tagliaferri,Thynn Thynn Yee,Pieter Willem Kamphuisen,Johanna G. van der Bom,Karin Fijnvandraat +44 more
TL;DR: The INSIGHT study analyzed the association between F8 mutation and inhibitor development in patients with nonsevere hemophilia A and found that among a total of 214 different F8 missense mutations 19 were associated with inhibitor development.
Journal ArticleDOI
A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate
TL;DR: A higher than expected incidence of factor VIII inhibitors associated with the use of a specific factor VIII concentrate in multitransfused haemophilia A patients is demonstrated and indicates the usefulness of evaluating newly introduced concentrates in prospective, randomized trials.